Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer

Authors:

Abstract
Prostate cancer is the most common cancer and the second leading cause of cancer death among men in the US.1 Quiz Ref ID Although 76% of the patients with prostate cancer were first diagnosed with localized cancer,2 approximately 30% of these patients experience disease recurrence after definitive treatments.3 Most recurrent prostate cancers initially respond to androgen-deprivation therapy (ADT) but eventually develop resistance, transforming from castration-sensitive to castration-resistant prostate cancer.4 Metastatic castration-resistant prostate cancer is associated with high mortality: a 5-year survival rate of 30%.2

This publication has 36 references indexed in Scilit: